|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||78.90 - 78.90|
|52 Week Range||78.78 - 97.30|
|Beta (5Y Monthly)||0.52|
|PE Ratio (TTM)||22.67|
|Forward Dividend & Yield||3.22 (3.47%)|
|Ex-Dividend Date||Mar. 04, 2021|
|1y Target Est||N/A|
Novartis (NVS) throws light on its pipeline progress, key areas of focus and long-term targets at its R&D day. Here, we discuss key highlights from the same.
Aurinia (AUPH) gains on rumors of a potential acquisition yet again. Reportedly, the company is being eyed by Novartis.
Shares of the autoimmune disease specialist Aurinia Pharmaceuticals (NASDAQ: AUPH) are up by a noteworthy 15.5% as of 1:10 p.m. ET Thursday afternoon. Rumors began to swirl about a possible buyout this morning after Novartis (NYSE: NVS) reportedly said during its research and development day that it will focus on smaller bolt-on acquisitions, instead of megadeals. Aurinia has repeatedly been the topic of the buyout rumor mill in 2021.